Suppression of eIF5A1 expression by the use of antisense oligonucleotides for the prevention of retinal cell death in the glaucomatous eye
US7381708B2 · kind B2 · utility
2Cited by
0References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 10, 2003 |
| Grant date | Jun 3, 2008 |
| Priority date | — |
| Expiry date | Jan 5, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/11
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention provides methods for preventing retinal ganglion cell death in the glaucomatous eye and methods for suppressing apoptosis-specific eIF5A1 expression through the use of antisense oligonucleotides targeted to human apoptosis-specific eIF5A1.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.